Prestige BioPharma Limited (KRX:950210)

Prestige BioPharma Statistics

Total Valuation

KRX:950210 has a market cap or net worth of KRW 149.04 billion. The enterprise value is 216.81 billion.

Market Cap	149.04B
Enterprise Value	216.81B

Important Dates

The last earnings date was Friday, September 19, 2025.

Earnings Date	Sep 19, 2025
Ex-Dividend Date	n/a

Share Statistics

KRX:950210 has 12.02 million shares outstanding. The number of shares has increased by 0.44% in one year.

Current Share Class	n/a
Shares Outstanding	12.02M
Shares Change (YoY)	+0.44%
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	30.40%
Owned by Institutions (%)	0.11%
Float	3.59M

Valuation Ratios

The trailing PE ratio is 33.50.

PE Ratio	33.50
Forward PE	n/a
PS Ratio	10.40
PB Ratio	0.29
P/TBV Ratio	0.40
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	9.72
EV / Sales	15.13
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.33

Financial Position

The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.28.

Current Ratio	1.27
Quick Ratio	1.05
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	-1.55
Interest Coverage	-8.73

Financial Efficiency

Return on equity (ROE) is 0.81% and return on invested capital (ROIC) is -6.62%.

Return on Equity (ROE)	0.81%
Return on Assets (ROA)	-5.71%
Return on Invested Capital (ROIC)	-6.62%
Return on Capital Employed (ROCE)	-11.47%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.02
Inventory Turnover	1.18

Taxes

Income Tax	-248.48M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -26.84% in the last 52 weeks. The beta is 1.03, so KRX:950210's price volatility has been similar to the market average.

Beta (5Y)	1.03
52-Week Price Change	-26.84%
50-Day Moving Average	13,861.40
200-Day Moving Average	14,254.55
Relative Strength Index (RSI)	35.38
Average Volume (20 Days)	134,983

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KRX:950210 had revenue of KRW 14.33 billion and earned 22.30 billion in profits. Earnings per share was 370.20.

Revenue	14.33B
Gross Profit	-12.24B
Operating Income	-66.59B
Pretax Income	3.92B
Net Income	22.30B
EBITDA	-44.78B
EBIT	-66.59B
Earnings Per Share (EPS)	370.20

Balance Sheet

The company has 173.71 billion in cash and 144.18 billion in debt, giving a net cash position of 29.53 billion or 2,457.12 per share.

Cash & Cash Equivalents	173.71B
Total Debt	144.18B
Net Cash	29.53B
Net Cash Per Share	2,457.12
Equity (Book Value)	508.31B
Book Value Per Share	6,828.29
Working Capital	44.68B

Cash Flow

In the last 12 months, operating cash flow was -52.14 billion and capital expenditures -40.74 billion, giving a free cash flow of -92.88 billion.

Operating Cash Flow	-52.14B
Capital Expenditures	-40.74B
Free Cash Flow	-92.88B
FCF Per Share	-7,727.38

Margins

Gross margin is -85.42%, with operating and profit margins of -464.80% and 155.64%.

Gross Margin	-85.42%
Operating Margin	-464.80%
Pretax Margin	27.38%
Profit Margin	155.64%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

KRX:950210 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.44%
Shareholder Yield	-0.44%
Earnings Yield	14.96%
FCF Yield	-62.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KRX:950210 has an Altman Z-Score of -0.28 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.28
Piotroski F-Score	4